AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33529093
Drug: Inactivated monovalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated monovalent EV-71 vaccine
Trial: 33093359
Drug: Non-aspirin
RxNorm normalized name: Non-Aspirin
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin
Trial: 32352811
Drug: Mindfulness practice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness practice (daily diary assessments)
Trial: 35533197
Drug: Glutamate infusion
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate infusion (0.125 M L-glutamic acid at 1.65 mL/kg/h)
Trial: 35533197
Drug: Glutamate infusion
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate infusion (in patients without diabetes)
Trial: 33115436
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB) treatment with irbesartan (150–300 mg)
Trial: 33413459
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) in the morning
Trial: 33413459
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) in the afternoon
Trial: 36088445
Drug: PolyPrime intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PolyPrime intervention (online video and medication reviews scheduled twice)
Trial: 32838783
Drug: Family-administered screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-administered screening with a 6.9 cm card for assessing baby's foot size.
Trial: 35098601
Drug: Fitness app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fitness app and activity tracker (treatment group)
Trial: 34209273
Drug: Alcoholic beer
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic beer (AB) - 330 mL/day
Trial: 34209273
Drug: Non-alcoholic beer
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-alcoholic beer (NAB) - 660 mL/day
Trial: 34115953
Drug: L-DGG (Er,Cr:YSGG-harvested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DGG (Er,Cr:YSGG-harvested DGG and root surface biomodified)
Trial: 35848935
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) group intervention, 14 sessions of 2 hours each
Trial: 33077119
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg ⋅ kg‐1)
Trial: 35261292
Drug: Warm saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm saline solution for postoperative care
Trial: 35918657
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of vancomycin
Trial: 35918657
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion (II) of vancomycin
Trial: 35442543
Drug: Atopalm cream®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopalm cream® (twice-daily application for three consecutive years)
Trial: 32967742
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of oral powder-based chocolate-flavoured CGMP for 4 weeks
Trial: 33012641
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose reduction of IAsp (2.6 ± 1.2 IU) before and after exercise
Trial: 33012641
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose reduction of IAsp post-exercise
Trial: 33012641
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 50% dose reduction of IAsp before and after exercise
Trial: 33012641
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose of IAsp (100%; 5.1 ± 2.4 IU)
Trial: 33830440
Drug: PEG 3350
RxNorm normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 3350 (0.7–1.5 mg/kg/day)
Trial: 33830440
Drug: Lactulose (0.7–2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (0.7–2.0 g/kg/day)
Trial: 33208855
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) treatment for menopausal hot flushes, twice a day for four weeks
Trial: 34412521
Drug: empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin 25 mg/d (n = 43)
Trial: 35513301
Drug: 2-g cephazolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g cephazolin
Trial: 35513301
Drug: Placebo (10-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10-mL normal saline)
Trial: 35869554
Drug: modified Xiao-Feng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified Xiao-Feng Powder (mXFP) with antihistamine Bilastine
Trial: 35869554
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with antihistamine Bilastine
Trial: 32891418
Drug: Pitavastatin/Fenofibrate combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin/Fenofibrate combination therapy (2/160 mg)
Trial: 32891418
Drug: Pitavastatin monotherapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin monotherapy (2 mg)
Trial: 33153482
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care psychosocial intervention (17-week program delivered at home by community health workers with tablet application)
Trial: 32492293
Drug: Hydroxychloroquine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days)
Trial: 35392739
Drug: Galcanezumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (240 mg loading dose, then 120 mg/month thereafter)
Trial: 32681228
Drug: Antibiotics/Hydroxychloroquine (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics/Hydroxychloroquine (ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks)
Trial: 32681228
Drug: Budesonide (Entocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Entocort CR 9 mg/day for 8 weeks, 6 mg/day for 2 weeks, 3 mg/day for 2 weeks)
Trial: 32681228
Drug: Antibiotics/Hydroxychloroquine (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics/Hydroxychloroquine (including crossover)
Trial: 32472292
Drug: Taurine 3000
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine 3000 mg/daily for 8 weeks
Trial: 32472292
Drug: Placebo (crystalline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (crystalline microcellulose/daily for 8 weeks)
Trial: 35545412
Drug: Dexmedetomidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.3 μg/(kg·h) (Dex1 group)
Trial: 35545412
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg/(kg·h) (Dex2 group)
Trial: 33217839
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion therapy (3 times a week for 3 menstrual cycles)
Trial: 33217839
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion therapy
Trial: 32574587
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dupilumab every 4 weeks + medium-potency topical corticosteroids (TCS)
Trial: 32230954
Drug: Leucine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine (6 g/day)
Trial: 37887975
Drug: Placebo (lactose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose, 6 g/day)
Trial: 34666412
Drug: Capsiate (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsiate (12 mg)
Trial: 34666412
Drug: Placebo (starch:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch: 12 mg)
Trial: 33932162
Drug: Nicotine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (6 mg) administered to cannabis users (CU)
Trial: 33932162
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to cannabis users (CU)
Trial: 33516285
Drug: Lumacaftor-ivacaftor therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor-ivacaftor therapy
Trial: 33516285
Drug: Placebo to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to treatment group
Trial: 32043288
Drug: saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin (5 mg/day) plus conventional therapy
Trial: 32043288
Drug: vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin D3 (2000 IU/day) plus saxagliptin and conventional therapy
Trial: 32043288
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional therapy with metformin (1-1.7 g/day) and/or insulin treatment
Trial: 35001410
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training + placebo (CT)
Trial: 35001410
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training + saffron supplementation (CTS)
Trial: 33351194
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy at 2 l.kg-1.min-1
Trial: 33351194
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy at 4 l.kg-1.min-1
Trial: 32527329
Drug: Skin cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin cancer preventive behaviors (wearing sun-blocking clothing, using sunscreen cream, wearing a cap, using gloves and sunglasses)
Trial: 34259408
Drug: Chinese medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medication
Trial: 32470923
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (70-ml, containing ∼4.1 mmol of nitrate)
Trial: 32470923
Drug: Placebo (70-ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (70-ml, containing ∼0.04 mmol of nitrate)
Trial: 33297409
Drug: Chlorogenic acids
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorogenic acids (CGAs) 270 mg tablets
Trial: 33790860
Drug: Long-acting octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting octreotide or lanreotide monotherapy for ≥4 months
Trial: 32006087
Drug: Ethosuximide (500,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethosuximide (500, 1000, or 1500 mg)
Trial: 32006087
Drug: Ethosuximide (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethosuximide (1500 mg/day)
Trial: 33259935
Drug: Palliative Volumetric
RxNorm normalized name: SETS,VOLUMETRIC,INTRAVENOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative Volumetric Arc Therapy (VMAT)
Trial: 33259935
Drug: 3-Dimensional Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-Dimensional Conventional Radiation Therapy (3DCRT)
Trial: 32248594
Drug: Pilocarpine (1.54%)
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine (1.54%) spray, used three times a day for 3 months
Trial: 32248594
Drug: Pilocarpine (1.54%)
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine (1.54%) spray
Trial: 33721085
Drug: Structured skills
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured skills training group (SSTG) based on dialectical behavioural therapy
Trial: 32108382
Drug: Skin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin patches of Xin Huang Pian
Trial: 34844893
Drug: Corticosteroid (CS;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS; cortivazol) injection
Trial: 32576219
Drug: SD-101 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 6% cream
Trial: 34379946
Drug: Proprietary combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen)
Trial: 34378307
Drug: BAX‐HI (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX‐HI (1 U/mL)
Trial: 34378307
Drug: NOVO‐HI (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOVO‐HI (100 U/mL diluted to 1 U/mL)
Trial: 34890532
Drug: 12-week supervised
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week supervised exercise training programme (moderate intensity combination aerobic/resistance exercise training programme)
Trial: 36399379
Drug: Automated virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated virtual reality cognitive therapy (gameChange)
Trial: 35396311
Drug: CKD-related video
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-related video decision aid followed by recording personal video declarations about goals of care and treatment preferences
Trial: 32885568
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (2 g combined probiotics daily)
Trial: 32308074
Drug: LED irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LED irradiation for 24 sessions (3 sessions per week) in addition to standard medical treatment
Trial: 32308074
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment for 8 weeks
Trial: 35943252
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg daily (fixed dosing)
Trial: 35943252
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing (10 mg/kg)
Trial: 35943252
Drug: Rifapentine and
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine and isoniazid regimen (1-month daily)
Trial: 34629430
Drug: Curettage +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curettage + platelet-rich plasma gel
Trial: 33932461
Drug: Diving method
RxNorm normalized name: Eucalyptus dives leafy twig oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diving method (500 mL of water administered every hour when the capsule reached the small bowel)
Trial: 35066365
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based transdiagnostic individually tailored Cognitive Behavioral Therapy (iCBT)
Trial: 32701116
Drug: Febuxostat 20
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 20 mg
Trial: 35431205
Drug: Customized on-site
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized on-site exercise program including manual and exercise therapy from physiotherapy
Trial: 34411745
Drug: Intensive patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive patient education (two, one-hour treatment sessions)
Trial: 34411745
Drug: Placebo patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patient education (two, one-hour treatment sessions)
Trial: 35965825
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (1.5 mg/kg lidocaine 10 minutes prior to induction, followed by 2 mg/kg/h until the end of surgery)
Trial: 34967575
Drug: Kali Haldi
RxNorm normalized name: Salsola kali pollen
DrugBank: Salsola kali pollen (DB10388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kali Haldi and aloe vera gel mixture, 3 times a day for 3 months
Trial: 34967575
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of hydrocortisone and hyaluronidase for 6 weeks with oral antioxidant supplements for 3 months
Trial: 32683644
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol 50 mg
Trial: 35636802
Drug: elobixibat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elobixibat (10 mg)
Trial: 33844469
Drug: Temozolomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5) plus Bevacizumab (10 mg/kg IV on days 1 and 15)
Trial: 33844469
Drug: Temozolomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5)
Trial: 32960632
Drug: Low glycaemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycaemic index preparations
Trial: 34227397
Drug: >0% to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >0% to 12.5% beta-blocker dose
Trial: 34227397
Drug: >25% to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >25% to 50% beta-blocker dose
Trial: 34227397
Drug: >12.5% to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >12.5% to 25% beta-blocker dose
Trial: 34227397
Drug: Full-dose beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose beta-blocker
Trial: 35708758
Drug: Targeted antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antifungal therapy driven by culture results (Control)
Trial: 32108122
Drug: Oral 50
RxNorm normalized name: fat supplement, oral 50% oral emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 50 mg tramadol
Trial: 34748549
Drug: Cognition-Targeted Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognition-Targeted Exercise (CTE) with Cognitive Behavior Therapy (CBT)
Trial: 34748549
Drug: Symptom-Targeted Exercise
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-Targeted Exercise (STE) with Cognitive Behavior Therapy (CBT)
Trial: 35639197
Drug: Siponimod (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siponimod (2 mg/day)
Trial: 36498624
Drug: Polaprezinc-containing therapy
RxNorm normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc-containing therapy (PQT)
Trial: 36498624
Drug: Bismuth-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing therapy (BQT)
Trial: 34826381
Drug: CVnCoV (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV (12 μg of mRNA, two 0.6 mL doses, days 1 and 29)
Trial: 34826381
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl, two 0.6 mL doses, days 1 and 29)
Trial: 32133780
Drug: Aspirin 150
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg oral daily from the first trimester
Trial: 33603941
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia (TIVA) with remifentanil and propofol (n = 35)
Trial: 35078079
Drug: Partial-oral treatment
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial-oral treatment
Trial: 38734138
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment
Trial: 36050653
Drug: Nivolumab after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab after temozolomide treatment
Trial: 32088302
Drug: Granulocyte Colony-Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte Colony-Stimulating Factor (G‐CSF) administered for 5 days every 3 months for 4 cycles (group A, n = 50)
Trial: 32088302
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone (group B, n = 50)
Trial: 35972531
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg of caffeine
Trial: 34151724
Drug: internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based Cognitive Behavioral Therapy (iCBT)
Trial: 35403350
Drug: Exenatide XR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide XR 2.0 mg weekly
Trial: 33291700
Drug: Chili (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chili (2 g)
Trial: 37531986
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% bupivacaine